Key statistics
On Friday, Abeona Therapeutics Inc (PCJ:STU) closed at 4.32, 21.35% above the 52 week low of 3.56 set on Nov 12, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.06 |
|---|---|
| High | 4.32 |
| Low | 4.06 |
| Bid | 4.30 |
| Offer | 4.36 |
| Previous close | 4.14 |
| Average volume | 400.00 |
|---|---|
| Shares outstanding | 54.19m |
| Free float | 48.19m |
| P/E (TTM) | 4.64 |
| Market cap | 278.00m USD |
| EPS (TTM) | 1.11 USD |
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Announcements
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
- Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
- Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
- Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
- Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
More ▼
